Syndrome de Miller Fisher avec anticorps anti GQ1b négatif au cours d’une pneumonie à Mycoplasma pneumoniae

Le Syndrome de Miller Fisher est caractérisé par l'association d'une ophtalmoplégie, d'une ataxie et d'une aréflexie ostéo-tendineuse. Une infection virale est le plus souvent retrouvée dans les jours ou semaines qui précèdent la symptomatologie. Nous rapportons un cas de syndrome de Miller Fisher survenu chez une femme de 75 ans, et ce au décours d'une infection pulmonaire à Mycoplasma pneumoniae. Les sérologies virales habituelles étaient négatives. Les anticorps anti GQ1b étaient absents. Il n'y avait pas de lésion du tronc cérébral à l'imagerie par résonnance magnétique. L'évolution clinique était favorable après perfusion d'immunoglobulines humaines polyvalentes et des macrolides en comprimés. La sérologie Mycoplasma pneumoniae doit être systématiquement recherchée dans le bilan du syndrome de Miller Fisher.Key words: Syndrome de Miller Fisher, Mycoplasma pneumoniae, ganglioside GQ1

Anomalies de l’électro-encéphalogramme en neurologie pédiatrique: à propos de 500 enregistrements à l’Hôpital Gynéco-Obstétrique et Pédiatrique de Yaoundé (Cameroun)

Introduction: Cette étude dont le but était d'évaluer la contribution de l'électroencéphalogramme (EEG) en neurologie pédiatrique et de déterminer les indications pertinentes chez l'enfant de 0 à 15ans. Méthodes: Il s'agit d'une étude rétrospective et descriptive réalisée au laboratoire d'électroencéphalographie de l'Hôpital Gynéco-Obstétrique et Pédiatrique de Yaoundé du 1er novembre 2011 au 15 mars 2012.Résultats: L'âge moyen des patients était de 70.2 mois avec des extrêmes de 0 et 180 mois. Le sexe ratio était de 1.04. Cent quatre vingt treize des 500 tracés de veille étaient anormaux 41 des 114 tracés de sommeil étaient anormaux et 78 des 500 tracés réalisés présentaient un rythme de fond ralenti pour l'âge. Cent cinquante tracés présentaient des anomalies épileptiques dont 81 focales, 35 multifocales et 34 des anomalies généralisées. Sur les 137 patients dont l'EEG était compatible avec une épilepsie, le lobe temporal était le plus souvent le siège d'anomalies épileptiques avec des épilepsies temporales et des épilepsies à pointes centro-temporales, venaient ensuite le lobe frontal, les épilepsies généralisées, les épilepsies du lobe occipital et l'hypsarythmie. Chez 13 des 150 patients avec des anomalies épileptiques à l'EEG, les anomalies retrouvées ne rentraient pas dans le cadre d'un syndrome épileptique particulier. Lorsque l'épilepsie était connue, la probabilité d'avoir un tracé EEG anormal était 1,44 fois plus élevée (OR=1.44 (0.83-2.52) même si la corrélation n'était pas statistiquement significative (p=0.1). En revanche lorsque l'épilepsie était suspectée, il y avait 3.43 fois plus de risques d'avoir un tracé anormal (OR=3.43 (2.27-5.18) avec une corrélation statistiquement significative (p< ;0.05). Les convulsions fébriles, les mouvements anormaux, le retard psychomoteur, les troubles déficitaires de l'attention avec hyperinésie, la perte de connaissance et les troubles du langage n'étaient pas significativement corrélés avec un risque accru d'avoir un EEG anormal. Conclusion: L'EEG a un rôle aussi bien dans la confirmation et la caractérisation de divers syndromes épileptiques et suspicions d'épilepsie que dans la discrimination des manifestations paroxystiques non épileptiques chez l'enfant. Les renseignements cliniques sont indispensables pour une lecture optimale du tracé.Key words: Enfants, épilepsies, électro-encéphalogramme, Camerou

Antifungal potential of extracts from four plants against Acremonium apii and Colletotrichum dematium, two major pathogens of celery (Apium graveolens L.) in Cameroon

In order to contribute to a sustainable control of plant diseases through the use of natural compounds, the antifungal potential of 11 extracts from 4 Cameroonian plants (Ageratum conyzoides, Callistemon citrinus, Cymbopogon citratus and Ocimum gratissimum) was evaluated in vitro against Acremonium apii and Colletotrichum dematium, respectively the causal agents of brown spots and anthracnose diseases of celery (Apium graveolens L.). Inhibition of fungi mycelial growth by essential oils, ethanol and aqueous extracts was assessed by using the supplemented media technique. Essential oils exhibited comparable activities against both fungi with minimum inhibitory concentration between 400 and 6000 ppm. Essential oil from O. gratissimum showed the highest inhibitory activity against both pathogens (400 ppm) followed by C. citratus (700 ppm and 800 ppm against A. apii and C. dematium, respectively), and then C. citrinus (6000 ppm). Ethanol extracts exhibited after the essential oils, the higher inhibitory activity against the two pathogens. Extract of C. citrinus was the most active with reductions of radial growth of 77.68% and 97.16% respectively against A. apii and C. dematium at 10000 ppm. Aqueous extracts at the same concentrations of ethanol extracts had little or no activity against both fungi. The fungitoxic potential of essential oils was higher than the one of the synthetic fungicide used as positive control. Our results suggest a promising potential of essential oils and ethanol extracts for botanicals control of celery fungal pathogens

Neonatal mortality in a referral hospital in Cameroon over a seven year period: trends, associated factors and causes.

Background: The fourth Millennium Development Goals targets reduction of the mortality rate of under-fives by 2/3 by the year 2015. This reduction starts with that of neonatal mortality representing 40% of childhood mortality. In Cameroon neonatal mortality was 31% in 2011.Objectives: We assessed the trends, associated factors and causes of neonatal deaths at the Yaounde Gynaeco-Obstetric and Pediatric Hospital.Methods: The study was a retrospective chart review. Data was collected from the hospital records, and included both maternal and neonatal variables from 1st January 2004 to 31st December 2010.Results: The neonatal mortality was 10%. Out-borns represented 49.3% of the deceased neonates with 11.3% born at home. The neonatal mortality rate followed a downward trend dropping from 12.4% in 2004 to 7.2% in 2010. The major causes of deaths were: neonatal sepsis (37.85%), prematurity (31.26%), birth asphyxia (16%), and congenital malformations (10.54%). Most (74.2%) of the deaths occurred within the first week with 35% occurring within 24hours of life. Mortality was higher in neonates with birth weight less than 2500g and a gestational age of less than 37 weeks. In the mothers, it was high in single parenthood , primiparous and in housewives and students..Conclusion: There has been a steady decline of neonatal mortality since 2004. Neonatal sepsis, prematurity, birth asphyxia and congenital malformations were the major causes of neonatal deaths. Neonatal sepsis remained constant although at lower rates over the study period.Key words: mortality, neonates, referral hospital, Cameroo

Neonatal mortality in a referral hospital in Cameroon over a seven year period: trends, associated factors and causes.

Background: The fourth Millennium Development Goals targets reduction by 2/3 the mortality rate of under-fives by 2015. This reduction starts with that of neonatal mortality representing 40% of childhood mortality. In Cameroon neonatal mortality was 31‰ in 2011.Objectives: We assessed the trends, associated factors and causes of neonatal deaths at the Yaounde Gynaeco-Obstetric and Pediatric Hospital.Methods: The study was a retrospective chart review. Data was collected from the hospital records, and included both maternal and neonatal variables from 1st January 2004 to 31st December 2010.Results: The neonatal mortality was 10%. Out-borns represented 49.3% of the deceased neonates with 11.3% born at home. The neonatal mortality rate followed a downward trend dropping from12.4% in 2004 to 7.2% in 2010. The major causes of deaths were: neonatal sepsis (37.85%), prematurity (31.26%), birth asphyxia (16%), and congenital malformations (10.54%). Most (74.2%) of the deaths occurred within the first week with 35% occurring within 24hours of life. Mortality was higher in neonates with birth weight less than 2500g and a gestational age of less than 37 weeks. In the mothers, it was high in single parenthood , primiparous and in housewives and students.Conclusion: There has been a steady decline of neonatal mortality since 2004. Neonatal sepsis, prematurity, birth asphyxia and congenital malformations were the major causes of neonatal deaths. Neonatal sepsis remained constant although at lower rates over the study period.Key words: mortality, neonates, referral hospital, Cameroo

Epilepsie chez les Enfants Atteints d’Infirmité Motrice Cérébrale : à Propos de 412 Observations à Yaoundé, Cameroun

Une étude prospective, descriptive et consécutive réalisée à l’Unité de Neurologie Pédiatrique de l’hôpital gynéco-obstétrique et pédiatrique de Yaoundé (Cameroun) du 1er janvier 2004 au 31 Décembre 2008 a permis de retenir 412 patients admis pour infirmité motrice cérébrale (IMC). L’IMC représentait 20,39% des pathologies neuropédiatriques. L’âge moyen des patients était de 31,7 mois. Les étiologies anténatales étaient de (5,51%), périnatales (65,25%), postnatales (29,22%) ; elles étaient dominées par l’asphyxie néonatale (43,68% de cas). L’épilepsie était l’une des principales affections associées à L’IMC. Elle était retrouvée chez 41,5% des patients. L’épilepsie était plus fréquente dans la tétraplégie spastique et l’hémiplégie cérébrale infantile. Par ailleurs 68,72% de patients ont fait la première crise épileptique au cours de leur première année de vie. Les convulsions néonatales, l’asphyxie néonatale et les infections néonatales ont été les facteurs de risque prédisposant les enfants avec IMC à faire l’épilepsie.Mots Clés enfants ; infirmité motrice cérébrale ; épilepsie ; Camerou

Distribution épidémiologique de l’infection à VIH chez les femmes enceintes dans les dix régions du Cameroun et implications stratégiques pour les programmes de prévention

Introduction: le Cameroun se situe dans un contexte d'épidémie  généralisée du VIH. La sous-population des femmes enceintes, facilementaccessible au sein de la population générale, représente une cible  robante pour mener la surveillance du VIH et estimer l'évolution épidémiologique. L'objectif de notre étude était d'évaluer la distribution épidémiologique du VIH chez les femmes enceintes.Méthodes: étude transversale menée en 2012 chez 6521 femmes  enceintes (49,3% âgées de 15-24 ans) en première consultation prénatale (CPN1) dans 60 sites des 10 régions Camerounaises. L'algorithme en série a été utilisé pour le sérodiagnostic du VIH.Résultats: la prévalence du VIH était de 7,8% (508/6521), avec une  différence non significative (p=0,297) entre milieu rural (7,4%) et milieu urbain (8,1%). En zone rurale, cette prévalence variait de 0,7% à  l'Extrême-Nord à 11,8% au Sud. Cependant, en zone urbaine elle variait de 4% à l'Ouest à 11,1% au Sud-Ouest. Suivant l'âge, la prévalence était plus élevée (11,3%) chez les femmes de 35-39 ans. Suivant le niveau de scolarisation, la prévalence du VIH était plus faible (4,4%) chez celles non-scolarisées, et plus élevée (9,3%) chez celles ayant un niveau  primaire. Selon la profession, l'infection était plus élevée chez les  coiffeuses (15,5%), secrétaires (14,8%), commerçantes (12,9%) et  institutrices/enseignantes (10,8%). Conclusion: la prévalence du VIH reste élevée chez les femmes enceintes au Cameroun, sans distinction entre milieux rural et urbain. Les stratégies de prévention devraient s'orienter préférentiellement chez les femmes enceintes âgées, celles du niveau d'instruction primaire, et celles du  secteur des petites et moyennes entreprises

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019

Background: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of the epidemic. Methods: To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 (threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). Findings: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections (0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met suggested thresholds for progress. Interpretation: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics. Funding: The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH

Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018

Abstract: Exclusive breastfeeding (EBF)—giving infants only breast-milk for the first 6 months of life—is a component of optimal breastfeeding practices effective in preventing child morbidity and mortality. EBF practices are known to vary by population and comparable subnational estimates of prevalence and progress across low- and middle-income countries (LMICs) are required for planning policy and interventions. Here we present a geospatial analysis of EBF prevalence estimates from 2000 to 2018 across 94 LMICs mapped to policy-relevant administrative units (for example, districts), quantify subnational inequalities and their changes over time, and estimate probabilities of meeting the World Health Organization’s Global Nutrition Target (WHO GNT) of ≥70% EBF prevalence by 2030. While six LMICs are projected to meet the WHO GNT of ≥70% EBF prevalence at a national scale, only three are predicted to meet the target in all their district-level units by 2030

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background: Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods: Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (>= 65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0-100 based on the 2.5th and 97.5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target-1 billion more people benefiting from UHC by 2023-we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings: Globally, performance on the UHC effective coverage index improved from 45.8 (95% uncertainty interval 44.2-47.5) in 1990 to 60.3 (58.7-61.9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2.6% [1.9-3.3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010-2019 relative to 1990-2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0.79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388.9 million (358.6-421.3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3.1 billion (3.0-3.2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968.1 million [903.5-1040.3]) residing in south Asia. Interpretation: The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people-the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close-or how far-all populations are in benefiting from UHC